Abstract: The present invention relates to a hemoglobin compositions stabilized against the formation of aggregates. The present invention further relates to methods of making such hemoglobin compositions.
Type:
Grant
Filed:
April 5, 1995
Date of Patent:
June 5, 2001
Assignee:
Somatogen, Inc.
Inventors:
Michael J. Gerber, Douglas L. Looker, Bruce A. Kerwin
Abstract: This invention relates to proteins with N-terminal modifications in their amino acid sequence that reduce or eliminate the methylation of the N-terminal methionine that occurs when such proteins are produced in bacteria such as E. coli.
Type:
Grant
Filed:
January 27, 1994
Date of Patent:
October 31, 2000
Assignee:
Somatogen, Inc.
Inventors:
Jacqueline F. Aitken, Izydor Z. Apostol, Julie A. Lippincott, Joseph D. Levine
Abstract: Mutated protein having a sequence with a non-proline amino acid replacement for a proline at amino acid position 4. The mutated protein is not methylated on its N-terminus when expressed in bacteria. The mutated protein is a mutation of a methylated protein that is at least partially methylated on its N-terminus when expressed in bacteria.
Type:
Grant
Filed:
February 29, 1996
Date of Patent:
September 22, 1998
Assignee:
Somatogen, Inc.
Inventors:
Jacqueline F. Aitken, Izydor Z. Apostol, Julie A. Lippincott, Joseph D. Levine
Abstract: The present invention relates to methods of lessening the severity and frequency of adverse effects associated with administration of extracellular hemoglobin comprising administration of a smooth muscle relaxant. Preferred smooth muscle relaxants are terbutaline and nifedipine, which can be administered in a prophylactic treatment, responsive regimented treatment or responsive intermittent treatment.
Abstract: The present invention relates to regulators of cellular gene transcription, particularly inhibitors of cellular gene transactivating factors and in particular to inhibition of gene transcription in a viral host cell that is subject to regulation by proteins or factors that originate from a virus as well as conjugates or fusion products of the inhibitors and internalization molecules, pharmaceutical compositions that can be used to alleviate or prevent the manifestation of disease states that are the result of unregulated DNA transcription as a result of transactivation, methods of treating diseases that are caused or exacerbated by the presence of transactivating factors, and regulated gene therapy to achieve long term drug delivery of the inhibitors of the present invention. This invention can be applied both to cells with genetic abnormalities or to cells infected with a virus. Preferably, at least one protein of the protein-protein interactions is a transactivating factor.
Type:
Grant
Filed:
February 18, 1994
Date of Patent:
February 10, 1998
Assignee:
Somatogen, Inc.
Inventors:
Maura-Ann H. Matthews, Gary L. Stetler, Spencer J. Anthony-Cahill, David C. Anderson
Abstract: The present invention relates to a method for the production of a substantially protoporphyrin IX free hemoglobin solution comprising: rapidly heating a crude protoporphyrin IX-containing hemoglobin solution for a relatively short time and at a relatively high temperature to reduce protoporphyrin IX-containing hemoglobin to insignificant levels in said protoporphyrin IX-containing hemoglobin solution.
Type:
Grant
Filed:
November 15, 1993
Date of Patent:
September 9, 1997
Assignee:
Somatogen, Inc.
Inventors:
James R. Ryland, Maura-Ann H. Matthews, Ulrich P. Ernst, Daniel E. Houk, David W. Traylor, Lee R. Williams
Abstract: The present invention relates to a method for stimulating hematopoiesis in a mammal comprising administration of a therapeutically effective amount of a hemoglobin, including recombinant hemoglobin, and methods for treating cytopenias. These cytopenias include anemia, thrombocytopenia, lymphopenia, neutropenia and the like. The stimulation of hematopoiesis can occur both in vivo and ex vivo, as in the treatment of cytopenias associated with disease states, in cell culture or ex vivo expansion of bone marrow cells.
Abstract: According to the present invention removal of nickel from a nickel-containing hemoglobin solution is accomplished by exposing the nickel-containing hemoglobin solution to a chelating agent, preferably a multidentate acetic acid based chelator such as EDTA. Methods are provided that allow obtaining essentially nickel-free hemoglobin from nickel-containing hemoglobin solutions, particularly hemoglobin solutions that result from large scale fermentation and/or purification.